Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS
I'm LongbridgeAI, I can summarize articles.Tiziana Life Sciences announced the launch of the Phase 2a BANYAN trial for intranasal foralumab in ALS, part of the Healey ALS MyMatch program. Presented at ALS Nexus 2026, the study aims to assess safety, immune-modulation biomarkers, neuroinflammation signals, and early clinical benefits versus placebo using a randomized 3:1 design across NEALS sites.
- Tiziana Life Sciences announced a Phase 2a BANYAN trial of intranasal foralumab in ALS within the Healey ALS MyMatch program. * Trial rationale and design were presented in a poster session at ALS Nexus 2026; no clinical results were reported. * Study targets safety, immune-modulation biomarkers, neuroinflammation signals, and early signs of clinical benefit versus placebo. * Randomized 3:1 foralumab-to-placebo design across NEALS sites; enrollment timing and site list to be detailed later. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240700OMX_____CNEWS_EN_GNW9814794_en) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)